Full-Time

Specialty Account Manager

Rare Disease

Posted on 9/23/2025

Deadline 10/31/25
Amgen

Amgen

10,001+ employees

Biotech company creating biologic medicines

Compensation Overview

$154.1k - $183.8k/yr

+ Bonus + Sales-based Incentive Plan

New Orleans, LA, USA

In Person

Category
Sales & Account Management (1)
Required Skills
Sales
Requirements
  • Doctorate degree & 2 years of collective account management experience, sales, & commercial experience
  • Master’s degree & 6 years of collective account management experience, sales, & commercial experience
  • Bachelor’s degree & 8 years of collective account management experience, sales, & commercial experience
  • Associate degree & 10 years of collective account management experience, sales, & commercial experience
  • Proficient in Microsoft Office
Responsibilities
  • Develops a comprehensive and effective territory business plan aimed at achieving and exceeding annual sales goals established by sales and business unit leadership.
  • Promotes TEPEZZA within approved labeling in a comprehensive, fair and ethical manner that is consistent with industry specific and corporate legal and regulatory guidelines.
  • Addresses issues related to access, pull-through, and reimbursement by coordinating with key stakeholders and matrix team members.
  • Develops strong customer relationships by better understanding the customer’s needs and goals and communicating those needs and goals to other team members.
  • Consistently meets or exceeds corporate sales goals.
  • Communicates territory activity in an accurate and timely manner as directed by management.
  • Drive product demand among targets through education on disease state and product information.
  • Provides feedback to sales and business unit leadership, colleagues, and other internal departments about changing environment and results.
  • Adheres to the Company’s compliance policies and guidelines as well as any other applicable guidelines, including but not limited to the PhRMA code.
  • Must be able to work closely with patient services and market access team members, and understand their roles, to achieve overall business goals,
  • Coordinate between accounts and relevant Amgen field teams to support full range of account needs,
  • Educate healthcare professionals and office staff on site of care options.
  • Attends medical congresses and society meetings as needed.
  • Manages efforts within assigned promotional and operational budget.
  • Maximizes use of approved resources to achieve territory and account level goals
  • Successfully completes all Company training classes.
  • Completes administrative duties in an accurate and timely fashion.
  • Functions as a contributing member of a high-performance team.
  • Perform such other tasks and responsibilities as requested by the Company.
Desired Qualifications
  • Buy-and-bill experience with documented success and/or biologic/infusion experience strongly preferred.
  • Sales experience in Endocrinology, Ophthalmology, and/or rare/specialty disease states preferred.
  • Site of care and reimbursement experience strongly preferred.
  • Experience working with institutions and integrated delivery networks preferred.
  • Pharma account management selling experience essential; must be able to coordinate across field teams to address full range of account needs.
  • Approximately 80% travel (may vary by territory), including some overnight and weekend commitments.
  • Professional, proactive demeanor.
  • Strong interpersonal skills.
  • Excellent written and verbal communication skills.

Amgen develops medicines that treat serious illnesses by using biologic therapies made from living cells. These therapies are designed to target specific disease processes, such as cancer, cardiovascular disease, and autoimmune conditions, and are produced through biotechnology methods that create proteins or antibodies. Amgen’s products are sold to patients and healthcare providers worldwide, with revenue funding ongoing research and development to discover new treatments. The company stands out by focusing on biologic medicines at a large scale and maintaining a steady pipeline of potential therapies across multiple disease areas, supported by global manufacturing and a commitment to bringing therapies to patients. Its goal is to improve patient outcomes by discovering and delivering new, effective treatments while reinvesting a significant portion of earnings into research and development.

Company Size

10,001+

Company Stage

IPO

Headquarters

Thousand Oaks, California

Founded

1980

Simplify Jobs

Simplify's Take

What believers are saying

  • MariTide's four-to-six-dose regimen could improve adherence and support obesity launch uptake.
  • IMDYLLTRA's Phase 3 survival benefit strengthens Amgen's oncology pipeline and commercial credibility.
  • Repatha growth, strong free cash flow, and AI efficiency support margin expansion.[1]

What critics are saying

  • Prolia's declining sales expose Amgen to erosion in its mature osteoporosis franchise.
  • MariTide still faces Phase 3, manufacturing, and tolerability execution risk before launch.
  • Tavneos regulatory scrutiny and tarlatamab safety concerns can limit near-term revenue conversion.

What makes Amgen unique

  • Amgen spans oncology, inflammation, rare disease, and general medicine across 100 countries.[1][3]
  • It combines biologics manufacturing with AI-driven discovery and development workflows.[1][5]
  • MariTide and IMDYLLTRA give Amgen distinct obesity and small-cell lung cancer growth options.[1]

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Amgen who can refer or advise you

Benefits

Professional Development Budget

Conference Attendance Budget

Company News

Yahoo Finance
Apr 10th, 2026
Amgen's lung cancer drug tarlatamab wins China approval, seen as $2B+ opportunity

Amgen's lung cancer drug tarlatamab has received approval from China's National Medical Products Administration, according to its development partner BeOne Medicines. The drug is a targeted immunotherapy for adults with extensive-stage small cell lung cancer that has progressed despite chemotherapy. Sold as Imdelltra in the US, tarlatamab is a bispecific antibody designed to connect cancer cells with immune cells, enabling the body's immune system to destroy the cancer. Neither Amgen nor Hong Kong-listed BeOne provided details on launch date or pricing for the Chinese market. Wall Street analysts estimate tarlatamab could generate annual sales exceeding $2 billion for Amgen.

Yahoo Finance
Apr 3rd, 2026
Amgen faces Tavneos liver injury warning as Zai Lab oncology collaboration expands IMDELLTRA pipeline

Amgen faces fresh safety concerns after the FDA warned of severe liver injuries, including vanishing bile duct syndrome, linked to Tavneos (avacopan) in late March 2026. The development adds regulatory risk to the company's investment profile. Separately, Zai Lab announced a global collaboration with Amgen to test its DLL3-targeting ADC alongside Amgen's IMDELLTRA in extensive-stage small cell lung cancer, underscoring the company's ongoing oncology expansion through external partnerships. Amgen's narrative projects $37.4 billion revenue and $8.2 billion earnings by 2028, requiring 2.3% yearly revenue growth. However, pessimistic analysts model revenues slipping to $34.4 billion with earnings near $5.2 billion, reflecting concerns around pricing pressure, biosimilar competition and rising research and development spend alongside the new safety issues.

Yahoo Finance
Mar 30th, 2026
Amgen stock up 24% since Jim Cramer's June recommendation, beats earnings estimates

Amgen, one of the world's largest pharmaceutical companies, has seen its shares rise 24% since Jim Cramer discussed the stock on Mad Money in June 2025. The company is currently developing the weight loss drug MariTide. Amgen's shares jumped 7.5% in November 2025 after posting third-quarter results that beat analyst expectations, with $9.6 billion in revenue and $5.64 earnings per share against forecasts of $8.98 billion and $5.04 respectively. In February 2026, shares rose 8% following fourth-quarter earnings that also exceeded estimates. Cramer expressed cautious optimism about the biotech company, noting its mid-single-digit earnings growth and potential upside from its GLP-1 drug development. Whilst calling Eli Lilly his preferred GLP-1 play, Cramer said investors "could do a lot worse than Amgen" for a bargain option.

Yahoo Finance
Mar 25th, 2026
Wells Fargo lifts Amgen price target to $390, cites $20B myasthenia gravis market potential by 2036

Wells Fargo has raised its price target on Amgen to $390 from $375, maintaining an Equal Weight rating. The firm cited emerging therapies including CD20, BAFF/APRIL and next-generation complement inhibitors as potential drivers that could expand the generalized myasthenia gravis market threefold over the next decade, potentially reaching $15 billion in US sales and $20 billion globally by 2036. Separately, Jefferies initiated coverage on Amgen with a Hold rating and $350 price target on 10 March, noting the stock has gained approximately 35% over the past six months. Last month, Amgen reported fourth-quarter adjusted earnings per share of $5.29, beating the $4.76 consensus estimate, on revenue of $9.9 billion versus $9.45 billion expected.

Yahoo Finance
Mar 15th, 2026
Amgen joins TrumpRx discount scheme and lifts dividend to $2.52 per share

Amgen has announced a $2.52 per-share second-quarter dividend and joined the government-run TrumpRx platform to offer discounted drugs including Amjevita, Aimovig and Repatha. The company is also preparing for its 11 March presentation at the Leerink Global Healthcare Conference in Miami. The moves come alongside double-digit revenue and earnings per share growth in 2025 and advances in obesity and oncology programmes. However, the TrumpRx discounting could pressure net pricing as Amgen invests heavily in late-stage trials and manufacturing expansion. Amgen's narrative projects $37.4 billion revenue and $8.2 billion earnings by 2028, requiring 2.3% yearly revenue growth. Some analysts see a tougher outlook, with revenue potentially drifting towards $34.4 billion and earnings around $5.2 billion.

INACTIVE